MetrioPharm Investor Relations News QI 2021


Holiday Greetings from CEO Dr. Wolfgang Brysch

Dear shareholders

As the first quarter of 2021 draws to a close, I would like to inform you about the latest developments at MetrioPharm AG.
Since the beginning of the coronavirus pandemic (in addition to prevention through vaccinations, social distancing and hygiene rules) the therapy of those already ill has been a frequent topic of scientific debate.

In the early phases, the focus has been on available drugs that had not been developed specifically to combat COVID-19. Unfortunately, however, many of those hopes were not fulfilled, and the need for innovative drug candidates is coming to the fore. Early treatment of COVID-19 disease could prevent severe courses that require intensive medical care and, in some cases, lead to death. A successful drug could, however, significantly change the way the pandemic is handled. It could also help to be better prepared for upcoming viral threats.

MetrioPharm AG wants to make its contribution to the pandemic response and thus the regulatory and logistical preparations of our clinical trial of MP1032 in COVID-19 are in full swing. The study will be conducted in up to eleven countries, with patient treatment expected to start by mid-2021.

In recent months, MetrioPharm AG has also been repeatedly involved in the therapy debate in the media. We are very pleased about this, because focused reporting provides this important topic with the necessary publicity. It motivates, as we hope in the right places, to set the political course accordingly. We will continue our efforts to keep you informed in a very timely manner.

I wish you all the best, good health, and relaxing holidays.

Yours Sincerely

Wolfgang Brysch



Your contact:

MetrioPharm AG Eva Brysch Investor Relations Managerin          

Lia Petridou
Corporate Communications & Press Relations

T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E press@metriopharm.com
W www.metriopharm.com



MetrioPharm AG Download PDF